{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:04:59Z","timestamp":1791324299410,"version":"4.3.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In clinical research of rare diseases, where small patient numbers and disease heterogeneity limit study design options, registries are a valuable resource for demographic and outcome information. However, in contrast to prospective, randomized clinical trials, the observational design of registries is prone to introduce selection bias and negatively impact the validity of data analyses.<\/jats:p>\n            <jats:p>The objective of the study was to demonstrate the utility of case-control matching and the risk-set method in order to control bias in data from a rare disease registry. Data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry were used as an example.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A case-control matching analysis using the risk-set method was conducted to identify two groups of patients with type 1 Gaucher disease in the ICGG Gaucher Registry: patients with avascular osteonecrosis (AVN) and those without AVN. The frequency distributions of gender, decade of birth, treatment status, and splenectomy status were presented for cases and controls before and after matching. Odds ratios (and 95% confidence intervals) were calculated for each variable before and after matching.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The application of case-control matching methodology results in cohorts of cases (i.e., patients with AVN) and controls (i.e., patients without AVN) who have comparable distributions for four common parameters used in subject selection: gender, year of birth (age), treatment status, and splenectomy status. Matching resulted in odds ratios of approximately 1.00, indicating no bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We demonstrated bias in case-control selection in subjects from a prototype rare disease registry and used case-control matching to minimize this bias. Therefore, this approach appears useful to study cohorts of heterogeneous patients in rare disease registries.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1750-1172-6-61","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T07:04:58Z","timestamp":1315897498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Reducing selection bias in case-control studies from rare disease registries"],"prefix":"10.1186","volume":"6","author":[{"given":"J Alexander","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N","family":"Hangartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,12]]},"reference":[{"key":"322_CR1","unstructured":"Office of Rare Disease Research. [http:\/\/rarediseases.info.nih.gov\/RareDiseaseList.aspx?PageID=1]."},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cct.2010.06.007","volume":"31","author":"YR Rubinstein","year":"2010","unstructured":"Rubinstein YR, Groft SC, Bartek R, Brown K, Christensen RA, Collier E, Farber A, Farmer J, Ferguson JH, Forrest CB, Lockhart NC, McCurdy KR, Moore H, Pollen GB, Richesson R, Miller VR, Hull S, Vaught J: Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials. 2010, 31: 394-404. 10.1016\/j.cct.2010.06.007.","journal-title":"Contemp Clin Trials"},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.jacc.2010.03.019","volume":"55","author":"G Thanassoulis","year":"2010","unstructured":"Thanassoulis G, Massaro JM, Cury R, Manders E, Benjamin EJ, Vasan RS, Cupple LA, Hoffmann U, O'Donnell CJ, Kathiresan S: Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J Am Coll Cardiol. 2010, 55: 2491-2498. 10.1016\/j.jacc.2010.03.019.","journal-title":"J Am Coll Cardiol"},{"key":"322_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1542\/peds.2007-2144","volume":"122","author":"H Andersson","year":"2008","unstructured":"Andersson H, Kaplan P, Kacena K, Yee J: Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008, 122: 1182-1190. 10.1542\/peds.2007-2144.","journal-title":"Pediatrics"},{"key":"322_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD: The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006, 160: 603-608. 10.1001\/archpedi.160.6.603.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"322_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.21280","volume":"83","author":"N Weinreb","year":"2008","unstructured":"Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S: A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008, 83: 890-895. 10.1002\/ajh.21280.","journal-title":"Am J Hematol"},{"key":"322_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A: Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004, 41: 4-14.","journal-title":"Semin Hematol"},{"key":"322_CR8","first-page":"1169","volume":"11","author":"TM Cox","year":"2010","unstructured":"Cox TM: Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs. 2010, 11: 1169-1181.","journal-title":"Curr Opin Investig Drugs"},{"key":"322_CR9","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010, 116: 4095-4098. 10.1182\/blood-2010-06-293902.","journal-title":"Blood"},{"key":"322_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ: A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010, 116: 893-899. 10.1182\/blood-2010-03-273151.","journal-title":"Blood"},{"key":"322_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN: Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007, 22: 119-126.","journal-title":"J Bone Miner Res"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009, 11: 92-100. 10.1097\/GIM.0b013e31818e2c19.","journal-title":"Genet Med"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ: Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009, 147: 561-570. 10.1111\/j.1365-2141.2009.07872.x.","journal-title":"Br J Haematol"},{"key":"322_CR14","unstructured":"Registries for Evaluating Patient Outcomes: A Users Guide. [http:\/\/www.ahrq.gov]."},{"key":"322_CR15","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A: The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000, 160: 2835-2843. 10.1001\/archinte.160.18.2835.","journal-title":"Arch Intern Med"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO: Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995, 122: 33-39.","journal-title":"Ann Intern Med"},{"key":"322_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","volume":"31","author":"TM Cox","year":"2008","unstructured":"Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N: Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis. 2008, 31: 319-336. 10.1007\/s10545-008-0779-z.","journal-title":"J Inherit Metab Dis"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM: Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011, 90: 52-60. 10.1097\/MD.0b013e3182057be4.","journal-title":"Medicine (Baltimore)"},{"key":"322_CR19","volume-title":"Epidemiology: An Introduction","author":"K Rothman","year":"2002","unstructured":"Rothman K: Epidemiology: An Introduction. New York: Oxford University Press; 2002."},{"key":"322_CR20","volume-title":"Pharmacoepidemiology","author":"B Strom","year":"2005","unstructured":"Strom B: Pharmacoepidemiology. 4 edition New Jersey: Wiley Publishers; 2005.","edition":"4"},{"key":"322_CR21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","volume":"138","author":"G Maldonado","year":"1993","unstructured":"Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol. 1993, 138: 923-936.","journal-title":"Am J Epidemiol"},{"key":"322_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S: Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006, 15: 291-303. 10.1002\/pds.1200.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"322_CR23","volume-title":"Epidemiology: Beyond the Basics","author":"M Szklo","year":"2006","unstructured":"Szklo M, Nietro F: Epidemiology: Beyond the Basics. Massachusetts: Jones and Bartlett; 2006."},{"key":"322_CR24","unstructured":"STROBE Statements. [http:\/\/www.strobe-statement.org]."},{"key":"322_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3122\/jabfm.2011.01.100080","volume":"24","author":"LM Baldwin","year":"2011","unstructured":"Baldwin LM, Dobie SA, Cai Y, Saver BG, Green PK, Wang CY: Receipt of general medical care by colorectal cancer patients: a longitudinal study. J Am Board Fam Med. 2011, 24: 57-68. 10.3122\/jabfm.2011.01.100080.","journal-title":"J Am Board Fam Med"},{"key":"322_CR26","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1212\/WNL.0b013e318205051d","volume":"76","author":"MS Freedman","year":"2011","unstructured":"Freedman MS: Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011, 76: S26-34.","journal-title":"Neurology"},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00467-010-1746-0","volume":"26","author":"O Mansoor","year":"2011","unstructured":"Mansoor O, Chandar J, Rodriguez MM, Abitbol CL, Seeherunvong W, Freundlich M, Zilleruelo G: Long-term risk of chronic kidney disease in unilateral multicystic dysplastic kidney. Pediatr Nephrol. 2011, 26: 597-603. 10.1007\/s00467-010-1746-0.","journal-title":"Pediatr Nephrol"},{"key":"322_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M: Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007, 82: 697-701. 10.1002\/ajh.20908.","journal-title":"Am J Hematol"},{"key":"322_CR29","unstructured":"Clinical Trials. [http:\/\/www.clinicaltrials.gov]."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-6-61.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:59:58Z","timestamp":1630515598000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-6-61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-6-61","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,12]]},"assertion":[{"value":"4 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"61"}}